Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma

Follicular lymphoma (FL) is traditionally considered treatable but incurable. In March 2021, the US Food and Drug Administration approved the use of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory (R/R) FL after ≥2 lines of therapy. Priced at $373 000, CAR T-ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Potnis, Kunal C., Di, Mengyang, Isufi, Iris, Gowda, Lohith, Seropian, Stuart E., Foss, Francine M., Forman, Howard P., Huntington, Scott F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011202/
https://www.ncbi.nlm.nih.gov/pubmed/36342852
http://dx.doi.org/10.1182/bloodadvances.2022008097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011202/
https://www.ncbi.nlm.nih.gov/pubmed/36342852
http://dx.doi.org/10.1182/bloodadvances.2022008097

Ejemplares similares